Payment overview · 2025
General Payments
$152.25
7 reported records · 6 companies
Healthcare provider profile · identity verified
Grace Dunn, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BELL, FL · NPI 1003009853
Verified facts
What the public records show
CMS Open Payments records show Grace Dunn, M.D. received $152.25 in general payments during 2025 across 7 reported records.
ACADIA Pharmaceuticals Inc accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $49.30 | 32.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.01 | 15.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.85 | 14.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.29 | 13.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.87 | 13.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.93 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.25 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 166 |
| Gabapentin | Gabapentin | 362 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 123 |
| Omeprazole | Omeprazole | 356 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 97 |
| Losartan Potassium | Losartan Potassium | 303 | 90 |
| Lisinopril | Lisinopril | 247 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 64 |
| Trazodone Hcl | Trazodone Hcl | 186 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 61 |
| Metformin Hcl | Metformin Hcl | 180 | 59 |
| Montelukast Sodium | Montelukast Sodium | 179 | 58 |
| Doxycycline Hyclate | Doxycycline Hyclate | 161 | 118 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 57 |
| Alprazolam | Alprazolam | 157 | 37 |
| Buspirone Hcl | Buspirone Hcl | 149 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 47 |
| Tramadol Hcl | Tramadol Hcl | 144 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 46 |
| Eliquis | Apixaban | 131 | 31 |
| Baclofen | Baclofen | 129 | 40 |
| Sertraline Hcl | Sertraline Hcl | 126 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 39 |
| Glipizide | Glipizide | 123 | 35 |
| Simvastatin | Simvastatin | 123 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 39 |
| Carvedilol | Carvedilol | 121 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 33 |
| Ozempic | Semaglutide | 99 | 25 |
| Furosemide | Furosemide | 97 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 29 |
| Famotidine | Famotidine | 90 | 36 |
| Prednisone | Prednisone | 86 | 50 |
| Mounjaro | Tirzepatide | 84 | 13 |
| Potassium Chloride | Potassium Chloride | 84 | 27 |
| Meloxicam | Meloxicam | 82 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 16 |
| Spironolactone | Spironolactone | 69 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 18 |
| Mupirocin | Mupirocin | 66 | 48 |
| Promethazine Hcl | Promethazine Hcl | 66 | 16 |
| Lovastatin | Lovastatin | 62 | 20 |
| Cephalexin | Cephalexin | 60 | 49 |
| Synthroid | Levothyroxine Sodium | 60 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 15 |
| Topiramate | Topiramate | 57 | 15 |
| Lorazepam | Lorazepam | 56 | 20 |
| Pregabalin | Pregabalin | 55 | 11 |
| Cefdinir | Cefdinir | 52 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 13 |
| Allopurinol | Allopurinol | 51 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 19 |
| Celecoxib | Celecoxib | 47 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 12 |
| Jardiance | Empagliflozin | 44 | 14 |
| Methocarbamol | Methocarbamol | 42 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 11 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Nystatin | Nystatin | 40 | 28 |
| Fluconazole | Fluconazole | 39 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 16 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 30 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 28 |
| Enalapril Maleate | Enalapril Maleate | 32 | 12 |
| Ezetimibe | Ezetimibe | 31 | 15 |
| Estradiol | Estradiol | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 28 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | 13 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Diazepam | Diazepam | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.25 · 7 records | ACADIA Pharmaceuticals Inc | DAYBUE, Fluad, Flucelvax, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, WaveWriter Alpha Prime 16, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error